Stocks  /  AMEX  /  Apimeds Pharmaceuticals US Inc.

Apimeds Pharmaceuticals US Inc.

Industry:   Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol:   APUSAMEX

 

Animal Usage:   Animal Testing, By-product

Our Opinion

Apimeds Pharmaceuticals US Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile. Furthermore, the company’s lead product, Apitox, is a bee venom-based toxin, meaning its final product is an animal by-product (venom) derived from the Apis mellifera (honeybee).

Supporting Evidence:

The company confirms in the following report that they utilize animal subjects for product testing and harvest animal-derived ingredients for their formulations.

“Results from an animal study entitled “Effect of bee venom and melittin on plasma cortisol in the unanesthetized monkey” published by Vick et al., indicate that melittin appears to stimulate the production of cortisol from the adrenal gland.” (Page 64) Read the full document

“Apitox is purified honeybee (Apis mellifera) venom manufactured as a lyophilized powder for reconstitution in 0.5% preservative-free lidocaine (lmg/mg) prior to intradermal dose injections that are administered up to 1,500 micrograms per weekly visit.” (Page 64) Read the full document

Company Description

Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Company Website: http://www.apimeds.co.kr/en/company.html

Contact:  info@apimedsus.com
Scroll to Top